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Abstract
Background: Diabetes is a major public health concern. In spite of continuous new drug development to treat
diabetes, herbal remedies remain a potential adjunct therapy to maintain better glycemic control while also imparting
few side-effects. Portulaca oleracea has been traditionally used to manage several diseases due to the anti-oxidant and
anti-atherogenic effects it imparts. To better understand the mechanisms associated with potential protective effect of
P. oleracea extract against diabetes, alloxan-induced diabetic rats were used in this study.
Methods: Forty Wistar rats (male, 7–8-wk-old, 140–160 g) were divided into four groups (n = 10/group): Group I (control),
Group II (P. oleracea-treated; gavaged with P. oleracea extract daily [at 250 mg/kg] for 4 weeks), Group III (diabetic
control; daily IP injection of alloxan [at 75 mg/kg] for 5 days) and Group IV (P. oleracea-pre-treated diabetic; gavaged
with P. oleracea extract daily [at 250 mg/kg] for 4 weeks and then daily IP injection of alloxan [at 75 mg/kg] for 5 days).
Body weight, food consumption, blood (serum) levels of glucose, C peptide, Hb A1C, insulin, tumor necrosis factor
(TNF)-α and interleukin (IL)-6 were determined for all groups.
Results: The results indicated that while Hb A1C, serum levels of glucose, TNF-α and IL-6 were all significantly decreased
in the P. oleracea-pre-treated diabetic rats, these hosts also had significant increases in C peptide and insulin compared to
levels in the counterpart diabetic rats. These results were confirmed by the histopathological assessments which showed
marked improvement of the destructive effect on pancreatic islet cells induced by alloxan.
Conclusion: P. oleracea extract is a general tissue protective and regeneartive agent, as evidenced by increasing β-cell
mass and therefore improved the glucose metabolism. Thus, stimulation of Portulaca oleracea signaling in β- cells may be
a novel therapeutic strategy for diabetes prevention.
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Background
Diabetes mellitus has become the third greatest “killer”
after cancer and cardio-/cerebro-vascular diseases [1]. It
is estimated that 5% of all deaths in the world are caused
by diabetes, a number which will increase by 50% in the
next 10 years [2]. At the time of clinical diagnosis, ap-
proximately 70% of the host’s total β-cell mass is
destroyed as a consequence of immune-mediated pro-
cesses [3]. As there are no certain cures for diabetes, an
overarching goal in the treatment of all types of diabetes
is preservation and even potential regeneration of β-
cells.
Natural products isolated from medicinal plant sources
have been used for the prevention and treatment of vari-
ous diseases/pathologies, including cancers, heart disease,
diabetes mellitus, and high blood pressure [4–6]. To date,
more than 800 species have been investigated and their
hypoglycemic effects reported [7].
Portulaca oleracea, (P. oleracea, Family Portulacaceae),
also known as Purslane, is a herbaceous plant distributed
throughout the world. It is eaten extensively around the
Mediterranean and tropical Asian countries and has been
used as a folk medicine in many countries. It contains
many biologically active compounds and is a source of
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many nutrients including oxalic acid, alkaloids, ω-3 fatty
acids, coumarins, flavonoids, cardiac glycosides, anthraqui-
nones, linolenic acid, mono-terpene glycosides, N-trans-
feruloyl tyramine, vitamins C and A, oleoresins-I and -II,
saponins, tannins, saccharides, triterpenoids, and glutathi-
one [8, 9]. The effects of P. oleracea extract have been eval-
uated in several model systems and is therefore listed as
one of the most useful medicinal plants and named “Global
Panacea” by the World Health Organization [10]. It is also
rich in antioxidant vitamins and omega-3 fatty acids [11]
and can be used for various curative purposes in health
care especially in preventing some cardiovascular, inflam-
matory diseases and maintaining a healthy immune system
[12, 13]. However, its usage for diabetes management was
not rigorously evaluated, hence needs further elucidation.
The studies reported in the literature were basically experi-
mental observational studies, that did not provide enough
mechanistic clarification for the hypoglycemic effect for P.
oleracea.
The antidiabetic effect of the ethanolic extract of Purslane
on high fat diet -induced diabetic rats was previously inves-
tigated by Hussein et al. [14]. They referred the antidiabetic
effect to high content of flavonoids, phenolic compounds,
melatonin and omega-3 fatty acids found in the ethanolic
extract. However, other bioactive compounds found in
purslane (dopamine, dopa, coumarins, alkaloids and sapo-
nins, polyphenols, flavonoids) may influence glucose
metabolism by several mechanisms, such as inhibition of
carbohydrate digestion and glucose absorption in the intes-
tine, stimulation of insulin secretion from the pancreatic ß-
cell, modulation of glucose release from liver, activation of
insulin receptors and glucose uptake in the insulin sensitive
tissues, and modulation of hepatic glucose output [14].
In another study of Lee et al. [15], the aqueous extract
of P. oleracea was found to prevent diabetic vascular
inflammation, hyperglycemia, and diabetic endothelial
dysfunction in type II diabetic db/db mice, suggesting its
protective role against diabetes and related vascular
complications and renoprotective effect on diabetic ne-
phropathy accelerated by renal fibrosis and inflammation
in type 2 diabetic db/db mice [16]. The crude polysac-
charide extract of this plant was also found to lower
blood glucose and modulate the metabolism of blood
lipids and glucose in alloxan- [17] as well as in STZ-
induced diabetic mice [18], whilst decreasing the levels
of total cholesterol, triglycerides, and fasting blood glu-
cose in type II diabetic mice [19]. Gu et al. [20] com-
pared the hypoglycemic and antioxidant activities of the
fresh and dried P. oleracea L. in insulin-resistant HepG2
cells and streptozotocin-induced C57BL/6 J diabetic
mice. Their results indicated that both fresh and dried P.
oleracea extract possessed antidiabetic and antioxidant
activities, besides stronger activity was observed in the
fresh herb [20].
The present study sought to determine the possible
protective and curative effects of P. oleracea extract
against diabetes, with a specific focus on its potential re-
generative effects on β-cells. For these analyses, a well-




Wistar rats (40 male, 7–8-wk-old, 120–150 g) were ob-
tained from the Abo Rawash Breeding Farm (Cairo,
Egypt). All rats were housed (five rats/25 × 30 × 30 cm
cage) under specific pathogen-free conditions in facilities
maintained at 21–24 °C with a 40–60% relative humidity
and 12 h light/dark cycle. All rats had ad libitum access
to standard rodent chow and filtered water and were
acclimated for 2 weeks prior to initiation of the experi-
ment. All procedures were approved by the Animal Care
Committee of Al Azhar University. The “Principles of
laboratory animal care” were followed, as well as specific
national laws where applicable.
For the experiment, rats were randomly allocated into
four groups (n = 10/group).
Group I: Control rats were kept on a balanced diet and
to be intraperitoneally (IP)-injected with 3.7 ml/kg
normal saline every two days for 4 weeks and then an
additional daily IP injections of saline for a subsequent
5 days.
Group II: Rats were to be gavaged with P. oleracea
extract at a daily dose of 250 mg/kg for 4 weeks and
then receive daily IP injections of saline for a
subsequent 5 days.
Group III: Rats were to be intraperitoneally (IP)-
injected with 3.7 ml/kg normal saline every two days
for 4 weeks and then made diabetic by daily IP
injection of alloxan (at 75 mg/kg) for 5 days [21].
Group IV: Rats were gavaged with P. oleracea extract
daily (250 mg/kg) for 4 weeks and then receive daily IP
injection of alloxan (at 75 mg/kg) for 5 days.
Preparation of P. oleracea extract
The aerial parts of the fresh plant were collected from
Al Aiat farms, Giza, Egypt. Samples were verified for
taxonomy by the Pharmacognosy department coordin-
ator, and a voucher specimen of the plant material has
been placed in the herbarium of Al- Azhar University.
For the extract, the parts (1000 g) were washed with
water, cut into small pieces, dried at 40 °C in an oven
and then powdered. The powder was decocted in puri-
fied boiling water (at a ratio of 1 g per 9 ml) for 30 min
and then allowed to cool to room temperature. The ma-
terials were then filtered through filter paper. The filtrate
volume (and mass) was measured before being aliquoted
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into glass bottles and concentrated in a rotary evapor-
ator under reduced pressure at 55 °C and dried in a bath
of warm water and stored at 2–8 °C. Based on the dens-
ity, volumes of the extract (and needed dilution made
with saline) could then be made for use in dosing the
rats at the daily dose of 250 mg/kg [22]. The yield of the
water extract of P. oleracea was approximately 22.8% of
plant powder. For the gavages over the 4-weeks period,
volumes of 4 ml were never exceeded.
Chemical analysis
The total phenols were determined according to the
method of Danial and Georg [23], while the total flavo-
noids were determined according to Zhisen et al. [24].
The fractionation of poly phenolic compounds were de-
termined by HPLC according to the method of Goupy et
al. [25], fractionation of flavonoids were determined by
HPLC according to method of Merken and Beecher
[26], while carotenoids were determined according to
Wettestein [27].
Induction of diabetes
Alloxan monohydrate has been used to induce experi-
mental diabetes due to its selective destruction of pancre-
atic islet cells. Alloxan was obtained from Algomhoria
Chemical Co. (Cairo, Egypt) and dissolved in normal
saline at a concentration of 100 mg/ml alloxan solution
[28] (at 75 mg/kg).
For the study, overnight fasted rats were injected IP
(immediately after alloxan preparation) with the alloxan
at a dose of 75 mg/kg, and then administered 50%
dextrose-saline subcutaneously within 12 h after each
alloxan injection to minimize/prevent mortality [29].
Blood glucose monitoring
At the end of the experiment the blood glucose level of
all groups was monitored after 8 h of fasting conditions.
The samples obtained from the tail vein using a digital
glucometer (Accu-chek® Advantage, Roche Diagnostic,
Mannheim, Germany). Rats with blood glucose levels >
200 mg/dl were considered diabetic.
Blood sampling
After12 h over night fasting, morning blood samples
were collected from retro-orbital venous plexus by capil-
lary tubes under light ether anesthesia, at the end of the
experimental period and before animal scarification for
pancreatic sampling. Blood was separated into two ali-
quots; one was anti-coagulated for HbA1c assessment
and the other for serum separation. The first aliquot was
heparinized and glycosylated hemoglobin Hb A1c has
been defined operationally as the fast fraction hemoglo-
bins HbA1 (HbA1a, A1b, A1c) that elute first during
column chromatography.
The second aliquot was allowed to clot at room
temperature and then centrifuged at 3000 rpm for 15 min;
resultant sera were stored at −80 °C until assayed. The
sera were eventually analyzed for C peptide (using a quan-
titative immuno-enzymatic colorimetric method using
NOVATEC IMMUNDIAGNOSTICA GMBH, Germany
cat number. DNOV112 [30] and insulin using the method
of Eastham [31]).
Serum levels of tumor necrosis factor (TNF)-α and
interleukin (IL)-6 was determined using commercial
ELISA kits (RayBio® Rat, RayBiotech, Norcross, GA,
USA) according to manufacturer protocols. The level of
sensitivity of the kit was less than 25 pg TNFα/ml and
less than 30 pg IL-6/ml.
Body weight and food consumption
Body weight was measured weekly and the food con-
sumption measured daily.
Pancreatic tissue sampling
At the end of the experimental period, the animals were
euthanized under general anesthesia, a midline incision ≈
4 cm in length was induced in the abdomen, and the
pancreas dissected out. Half of the pancreatic tissue (in-
cluding tail part) was fixed in 10% neutral formalin and
subsequently embedded in paraffin. Tissue sections of
5 μm were then prepared and stained by hematoxylin
and eosin (H&E). Other sections underwent Masson
trichrome (MT) staining to confirm a presence of any fi-
brotic tissues and to assess blood vessels in the tissue.
Immunohistochemical detection of proliferative activity
of the pancreatic cells was performed by using anti-Ki67.
Morphometric assessment was done on (H&E) stained
slides using the image analyzer optical micrometer (TS
view), objective lens of magnification 10 and eye piece of
magnification of 12.5 binuclear microscope. The number
of islets per fixed square area of 11703.6 μm2 was counted.
Average area of the islets was determined by measuring
the area of 4 islets in each section and totally 20 islets in
each group. All measurements for each group were aver-
aged and these results were subjected to statistical analysis.
Statistical analysis
All results were expressed as mean ± SEM. Statistical ana-
lyses were performed using a one-way analysis of variance
[ANOVA] followed by a Bonferroni post hoc multiple
comparison test. All analyses were performed using com-
puter program SPSS [version.18]). A p-value < 0.05 was
considered as statistically significant.
Results
The chemical composition of P. oleracea was analysed to
find the active ingredients in this plant. The aqueous ex-
tract showed that total acidity was 0.15%, and pH value
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was 4.9. The antioxidant components were found to in-
clude total phenol (3.2 mg/100 g), flavonoids (6.2 mg/
100 g) total chlorophyll (280 mg/100 g) and total caroten-
oids (45. mg/100 g) (as shown in Table 1). The phenolic
compound were fractionated to catechein, chlorogenic,
salcylic and pyrogallol while flavonoids were fractionated
to rosmarinic, rutin, quercitrin with their respective levels,
as illustrated in Table 2.
Effect of Portulaca Oleracea (P. Oleracea) on body weight
and food intake (Table 3)
The present study showed a significant decrease in the
body weight in control rats that received P. Oleracea ex-
tract (Group II) (P < 0.05) from 195.4 ± 11.5gm to 180.4 ±
10.5 gm, when compared to control rats after four weeks
of the experimental period. The induction of diabetes
(group III) showed a significant reduction (P < 0.05) of
body weight from 200.4 ± 12.9 gm to 165 ± 10.8gm, when
compared to control rats. Moreover, the diabetic rats
which were pretreated with P. Oleracea extract (group IV)
were normalized (P < 0.05) from to 165 ± 11.8 gm to
202.10 ± 13.8, when compared to diabetic rats, while
the decrease (P > 0.05) from 200.4 ± 12.9 gm to 210.4 ± 9.9
gm was nonsignificant when compared to control group.
As regards to food intake, P. Oleracea extract supple-
mentation to rats showed a nonsignificant (P > 0.05)
increase (from 60.25 ± 1.04 gm to 61.50 ± 0.54 gm),
when compared to control rats, whereas diabetic group
showed a significant increase of food intake (P < 0.05)
from 60.25 ± 1.04 gm to 80.50 ± 0.94 gm, when com-
pared to control rats. Moreover, the diabetic rats pre-
treated with P. Oleracea extract showed nonsignificant
increase (P > 0.05) from 60.25 ± 1.04 gm to 62.25 ± 0.7
gm, when compared to control group but showed a sig-
nificant reduction from 80.50 ± 0.94 gm to 62.25 ± 0.7
gm, when compared to diabetic rats.
Effect of P. Oleracea extract on glucose homeostasis
indicators (glucose, C peptide, Insulin) as well as
inflammatory markers (TNF-α and IL-6) (Table 4)
P. Oleracea extract supplementation to control rats
(group II) for one week showed a non significant
difference in the assessed parameters (blood glucose, C
peptide, Insulin, TNF-α and IL-6), when compared to con-
trol rats. Therefore, all experimental groups were com-
pared to P. Oleracea-control only. The induction of
diabetes showed a significant increase (p < 0.05) in blood
glucose level from 109.0 ± 1.3 mg/dl to 293.2 ± 2.4 mg/dl,
when compared to PO- control rats. Pretreatment of dia-
betic rats with P. Oleracea extract for 4 weeks showed a
significant reduction (P < 0.05) of blood glucose level from
293.2 ± 2.39 mg/dl to 125.0 ± 1.3 mg/dl when compared to
diabetic rats.
P. Oleracea extract supplementation to control rats
(group II) for four weeks showed nonsignificant increase
(P < 0.05) in serum C peptide level from 0.97 ± 0.03 to
1.00 ± 0.04 when compared to control rats, whereas dia-
betic rats showed a significant decrease (P < 0.05) from
1.00 ± 0.04 to 0.48 ± 0.02 when compared to P. Oleracea
- control rats. This drastic decrease was significantly re-
versed to control levels in the P. Oleracea-diabetic rats
(from 0.48 ± 0.02 to 0.94 ± 0.02), when compared to dia-
betic rats.
As regards to serum HbA1c, the diabetic group
showed a significant increase of serum HbA1c (P < 0.05)
from 5.01 ± 0.07 to 10.35 ± 0.12, when compared to P.
Oleracea-control rats. The latter high perecentage of
HbA1c was significantly reduced to 6.97 ± 0.02 in P.
Oleracea- diabetic rats, which remained still significantly
higher than the P. Oleracea- control group.
In comparison to P. Oleracea - control group, the
serum insulin level in the diabetic group showed a sig-
nificant decrease (P < 0.05) from 36.02 ± 0.08 to 18.97 ±
0.09. This significant decrease was successfully reversed
in the diabetic rats upon pretreatment with P. Oleracea
extract for 4 weeks, as it showed a significant increase
(P < 0.05) of serum insulin level from 18.97 ± 0.09 to
33.5 ± 0.08 when compared to diabetic rats.
Table 1 Chemical composition of aqueous extract of P.oleracea





Total phenolic compounds (as gallic acid) 3.2
Total flavonoids (as quercetin) 6.2
Total chlorophyll 280
Total carotenoids 45
Table 2 Fractionation of aqueous extract of P. oleracea polyphenol
and flavonoids components by HPLC (mg/100 g wet weight)
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As for the effect on TNF-α, the diabetic rats showed a
significant elevation in the TNF-α levels (P < 0.05) from
34.77 ± 0.21 pg/ml to 49.70 ± 0.55 pg/ml when compared
to control rats. The P. Oleracea- diabetic rats showed a
significant decrease in TNF-α level from 49.70 ± 0.55 pg/
ml to 35.2 ± 0.24 pg/ml, when compared to diabetic rats;
this corrected level was nonsignificant from P. Oleracea
-control levels.
Concerning the effect on IL-6, the diabetic group
showed a significant increase from 14.91 ± 0.12 pg/ml to
28.9 ± 0.34 pg/ml, an elevation that was significantly de-
creased to 16.26 ± 0.17 pg/ml upon pretreatment with P.
Oleracea (P < 0.05).
Histopathological results
Microscopic examination of pancreatic tissues of dia-
betic group showed variable sized pancreatic islets with
arteriosclerosis (Fig. 1b), atrophy and reduction of its
cellular components with areas of necrosis (Fig. 1c)
compared to normal patterns (Fig. 1a). Some pancreatic
tissues showed vacuolation and decrease vasculature
with cellular infiltration with cells as lymphocytes and
mononuclear cells with focal areas of degeneration, con-
gestion and necrosis (Figs. 1d and e).
Pre-treatment with the extract for four weeks prior to
induction of diabetes resulted in pancreatic morphologies
resembling those of normal rats. Figure 2 panel describes
the ameliorative process of β-cells after P. Oleracea extract
administration in diabetic rats; increased vasculature
in pancreatic islets is shown in Fig. 2a, reaching near-
normal morphology of pancreatic islets as seen in
Fig. 2b. Figures 2c and d illustrate the hypertrophy and
hyper-cellularity along with increased blood vessel pres-
ence in the pancreas of P. Oleracea extract pre-treated
rats. Similarly, there was a high level of proliferative activ-
ity among pancreatic islet cells as indicated by the in-
creased levels of Ki-67 immunostaining (Fig. 2e).
The morphometric analysis, illustrated in Table 5, con-
firms the histological findings and reflects further the
ameliorative impact of P. Oleracea extract on the viable
pancreatic islets number and areas. It shows nonsignificant
difference between control and P. Oleracea-control in
terms of mean number of pancreatic islets and mean aver-
age of pancreatic islets area. As for the diabetic group it
showed a significant decrease in mean number of islets
(25.8%) as well as mean average of islets areas (47.5%),
compared to P. Oleracea -control group. Interestingly, these
decreases were significantly elevated, upon pretreatment
with P. Oleracea for 4 weeks, to reach levels higher than
the control levels.
Discussion
Irrespective of the type of diabetes, β-cell mass preserva-
tion and/or increase are known to be important targets
in management of diabetes as long as it reduces chronic
microvascular complications in the eyes, kidneys and
nerves [32].
The current study showed significant increases in
blood glucose levels after alloxan injection of the rats.
Etuk and Muhammed [33] and Adeyi er al. [34] attrib-
uted this increase in glucose levels to the reactive oxygen
species induced by alloxan; this, in conjunction with a
simultaneous massive increase in cytosolic calcium con-
centrations led to rapid destruction of pancreatic islet
cells and a concomitant reduction in synthesis/release of
insulin. This was confirmed here by histopathological re-
sults in alloxan-treated rats, as there were marked re-
duction in the size of cellular components of the islet
cells along with variable levels of degeneration and the
appearance of apoptotic cells. Such outcomes were in
line with those of Adeyemi et al. [35] who noted also a
significant reduction in the numerical density of islet
cells (number/pancreas), islet cell area and diameter and
β-cell density, in diabetic rats.









Body weight (g) at the beginning of experimental period 200.4 ± 12.9 a195.4 ± 11.5 a170.4 ± 10.5 a165.0 ± 11.8
Body weight (g) at the end of experimental period 210.4 ± 9.9 a180.4 ± 10.5 a165.0 ± 10.8 b202.1 ± 13.8
Food intake (g/d) at the beginning of experimental period 60.2 ± 1.0 a61.5 ± 0.5 a80.5 ± 0.9 b62.2 ± 0.7
Values are presented as means ± SEM
aValue significantly different vs. PO-control group or bfrom diabetic group, at P < 0.05
Table 4 Effect of treatments on blood glucose, HbA1c, serum









Blood Glucose 119.8 ± 1.0 109.0 ± 1.3 a293.2 ± 2.4 a,b125.0 ± 1.3
C peptide
(ng/mL)
0.97 ± 0.03 1.00 ± 0.04 a,0.48 ± 0.02 b0.94 ± 0.02
Hb A1c (%) 4.99 ± 0.06 5.01 ± 0.07 a10.35 ± 0.12 a,b6.97 ± 0.02
Insulin (mIU/L) 35.50 ± 0.09 36.02 ± 0.08 a18.97 ± 0.09 b33.50 ± 0.08
TNFa (pg/ml) 34.90 ± 0.17 34.77 ± 0.21 a49.70 ± 0.55 b35.20 ± 0.24
IL- 6 (pg/ml) 15.02 ± 0.13 14.91 ± 0.12 a28.90 ± 0.34 b16.26 ± 0.17
Values are presented as means ± SEM
aValue significantly different vs. PO- control group or bfrom diabetic group,
at P < 0.05
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Interestingly, the P. oleracea extract pretreatment to dia-
betic rats here resulted in significant decreases in blood
glucose levels. The possible contributing mechanisms is
hypothesized to be due to the potentiation of insulin
secretion from β-islet cells and consequent enhanced
transport of blood glucose to peripheral tissues. The
ameliorative and preventive effect of P oleracea against
pancreatic islet tissue atrophy and necrosis in diabetic rat
was represented on the histological images showing in-
creased vasculature in pancreatic islets to levels reaching
near those seen in normal rat, added to hypertrophy and
hyper-cellularity with increased blood vessel presence.
These effects could rationalize the improved β-cell num-
ber and size and hence better insulin secretion and better
glycemic control.
In the current study the chromatographic analysis of
the aqueas extract revealed phenolic compound
fractionated to catechein, chlorogenic, salcylic and pyro-
galol while flavonoids were fractionated to rosmarinic,
rutin, quercitrin; these results are in agreement to the
results obtained by Naciye [36] and Abd El-Aziz et al.
[37].
Elkhayat et al. [38] attributed the antihyperglycemic ef-
fect of P. oleracea chloroformic extract to its high concen-
tration of polysaccharides that were able to modulate
blood lipid metabolism and decrease blood glucose. More-
over, chromatographic fractionation of the chloroform ex-
tract of Portulaca oleracea L. growing in Egypt afforded a
new clerodene diterpene portulene, in addition to the
known compounds lupeol, β-sitosterol, and daucosterol,
which were reported for the first time from this plant. In
another study of Shen and Lu [39] they attributed the
hypoglycemic and hypolipidemic effect of the aqueous ex-





Fig. 1 a: showing normal pancreatic tissue (H&E ×125). b: Tissue showing arteriosclerosis of medium-sized blood vessel and its branches in diabetic
rat. c: Tissue with severe atrophy, depletion of cells, and necrosis in pancreatic islet of diabetic rat. d: Tissue with cell vacuolation and
perivascular dropout and decreased vasculature among pancreatic islets, along with cellular infiltration by mononuclear cells in exocrine
tissue in diabetic rat (Masson trichrome (MT) staining; 40× magnification). e: Tissue showing congested dilated blood vessels in diabetic
rat (MT staining; 400× magnification)
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oleracea. Moreover, they rationalized the improvement of
insulin resistance in rats with T2DM, due to the amelior-
ation of lipid metabolism and decrease free fatty acids, ef-
fects that are induced by the components of P. oleracea;
ω-3 unsaturated fatty acid 6, vitamin E, vitamin C, caro-
tene, glutathione. In our current study, the increased
number of Ki 67 islet cells, with compensatory
hyperplesia and hypertrophy support these data and
provide a plausible explanation to the apparent
hypoglycemic efficacy of P.oleracea.
Measures of serum C-peptide has been widely used as
a marker of insulin secretion [40]. The present study
revealed that induction of diabetes led to significant




Fig. 2 a: PO extract treated rats, showing increased vasculature in pancreatic islets to levels reaching near those seen in normal rat (H&E stain;
400× magnification). b: high power view, showing hypertrophy and hypercellularity of regenerating pancreatic islets (H&E×400). c: PO pretreated
diabetic case showing high number and proliferative activity of pancreatic cells (Ki 67 immunostaining original magnification ×400). d: PO pretreated
diabetic case showing hypercellularity of regenerating pancreatic islets. (H&E original magnification ×125). e: PO pretreated diabetic rats showing
increased number of regenerating pancreatic islets (H&E ×125)









The mean number of Pancreatic islets 2.9 ± 0.07 3.1 ± 0.06 a2.3 ± 0.08 a,b3.9 ± 0.09
The mean average of pancreatic islets area 159.9 μm± 3.3 162.3 μm± 3.5 a85.1 μm± 3.4 a,b180.5 μm± 4.8
Values are presented as means ± SEM
aValue significantly different vs. PO- control group or bfrom diabetic group, at P < 0.05
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compared to control group. These results were consist-
ent with those of Gabr et al. [41] who explained that this
reduction was due to the destruction of the islet cells.
During diabetes, glycosylated hemoglobin is formed
progressively and irreversibly over a period of time and
is stable till the life of the RBC and is unaffected by diet,
insulin or exercise on the day of testing [42]. Therefore,
it is routinely used as a marker for long-term glycemic
control [43]. The significant increase in HbA1C levels in
diabetic rats and its reversion in rats pre-treated with
the extract; suggest that the overall blood glucose levels
were being better controlled most likely due to improve-
ments in insulin secretion in these hosts.
As there is a significant association between β-cell
damage and inflammation, this study sought to assess
the host circulating levels of pro-inflammatory cytokines
TNF-α and IL-6 as they are known to play an important
role in the pathogenesis/progression of insulin resistance
[44, 45]. The present study showed elevated levels of
serum TNF - α and IL-6 in the diabetic rats. These re-
sults were in agreement with Pennathur and Heinecke
[46] and Mirza et al. [47]. Moreover, Sridevi et al. [48]
reported that hyperglycemia leads to increased levels of
monocytes that secrete increased amounts of TNF − α
and IL-6 via up-regulation of protein kinase (PKC-α and
PKC-β), P38 MAPK, and nuclear factor (NF)-κB.
Pretreatment with the aqueous extract of Portulaca
oleracea, in the present study, induced significant reduc-
tion in serum levels of TNF-α and IL-6. These results
were supported by the study of Lee et al. [49] who stated
that pretreatment with the aqueous extract of Portulaca
oleracea, inhibits TNF-α- induced production of intracel-
lular reactive oxygen species (ROS) and over-expression of
intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule (VCAM)-1, and E-selectin in human
umbilical vein endothelial cells (HUVECs) in a dose-
dependent manner.
These results were also supported by the study of Xiao
et al. [50] who reported that P. oleracea has a specific
protective effect on damaged adipose cell induced by
hyperlipdemic conditions. They reported the efficacy of
P. oleracea to increase the cell viability and improve dys-
lipidemia with different degrees, through antiinflammm-
tory effect, hence it lowers the levels of TNF- α and IL-6
that adipose cell secretes. A similar ameliorative effect
was provided by the study of Oshaghi et al. [51], who
tested the aqueous extract of Anethum Graveolens L. in
diabetic rats and proved its potential antidiabetic, anti-
oxidant and antiglycation effects.
The body weight is a sensitive indicator that reflects
the state of health of experimental animals and the de-
crease in body weight correlates with defects in body
metabolism [52]. The expected reduction of body weight
after alloxan injection was in agreement with Hassan
and Emam. [53] and Ojo et al. [54] who attributed this re-
duction to the amelioration of hyperglycemia. The in-
crease in the blood glucose resulting from the defective
cellular uptake of glucose, forces the cells to utilize amino
acids and fatty acids as a source of energy which eventu-
ally leads to the reduction of fats and tissue proteins which
normally represents about 30 to 40% of total body weight.
Thus, the excessive breakdown of tissue proteins due to
diminished insulin response as well as the unavailability of
carbohydrate for energy metabolism in diabetes mellitus
results in decreased body weight. Interestingly, P oleracea
administration to control rats caused a significant reduc-
tion in body weight, an effect that was resembled in the
experimental research of Bai et al. [55] as well as clinical
study of Esmaillzadeh et al. [56].
Regarding to the food intake, alloxan injection to nor-
mal rats in this study showed marked hyperphagia which
may be attributed to the hyperglycemia. Guyton and Hall
[57] explained this hyperphagia on physiological basis that
the decrease in blood glucose concentration causes hun-
ger, which has led to the so called glucostatic theory of
hunger and feeding regulation. The satiety center are sen-
sitive to arterio-venous gradient of blood glucose level, so
high arterio-venous blood glucose gradient stimulates the
satiety center and inhibits the feeding center inducing an-
orexia. In diabetes, although the blood glucose level is
high, polyphagia is increased because the arterio-venous
gradient is low as the cells cannot use the glucose due to
absence of insulin.
Conclusion
Portulaca oleracea is a general tissue protective and re-
generative agent, as evidenced by increasing β cell mass
and therefore improved the glucose metabolism. Thus,
stimulation of P. oleracea signaling in β- cells may be a
novel therapeutic strategy for diabetes prevention.
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